| __timestamp | Bausch Health Companies Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 20140000 |
| Thursday, January 1, 2015 | 2682700000 | 37173000 |
| Friday, January 1, 2016 | 2810000000 | 48616000 |
| Sunday, January 1, 2017 | 2582000000 | 108488000 |
| Monday, January 1, 2018 | 2473000000 | 244622000 |
| Tuesday, January 1, 2019 | 2554000000 | 287000000 |
| Wednesday, January 1, 2020 | 2367000000 | 354000000 |
| Friday, January 1, 2021 | 2624000000 | 186000000 |
| Saturday, January 1, 2022 | 2625000000 | 151000000 |
| Sunday, January 1, 2023 | 2917000000 | 232600000 |
| Monday, January 1, 2024 | 267474000 |
Unveiling the hidden dimensions of data
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry players is crucial. From 2014 to 2023, Bausch Health Companies Inc. and Ionis Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. Bausch Health's SG&A expenses have consistently hovered around the $2.5 billion mark, peaking at $2.9 billion in 2023, reflecting a steady investment in operational activities. In contrast, Ionis Pharmaceuticals has seen a dramatic increase, with expenses rising from a modest $20 million in 2014 to $354 million in 2020, before stabilizing around $230 million in 2023. This 17-fold increase highlights Ionis's aggressive expansion and investment in its administrative capabilities. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.
Sanofi and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Bausch Health Companies Inc.
Bausch Health Companies Inc. or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Galapagos NV